CEO Christian Behrenbruch purchases ~68k shares in two tranches totaling ~$997k at Telix Pharmaceuticals
Christian Behrenbruch, MD and Group CEO of Telix Pharmaceuticals, deployed nearly $1 million in open-market share purchases over two trading days, acquiring approximately 68,000 shares. As the chief executive, Behrenbruch is in a position with direct operational knowledge of the company and has chosen to commit personal capital rather than rely solely on compensation. The transaction represents material personal investment by the highest-ranking executive, moving beyond routine equity compensation. While both purchases occurred at modest price levels, the filing records the factual activity: a C-suite officer making significant equity purchases in his own company within a short timeframe.